IN A PK/PD STUDY, TOUJEO® DEMONSTRATED A GLUCOSE-LOWERING EFFECT THAT
LASTED UP TO 36 HOURSa

Toujeo® at steady state has a different activity profile than an equivalent dose of Lantus®1,2

Distribution profile of Toujeo® in a PK/PD study

Graph of distribution profile of Toujeo in a PK/PD study
aThe clinical significance of these PK/PD data has not been established.
  • Once-daily Toujeo® should be injected at the same time each day1
  • Toujeo® has a half-life of 19 hours ±6.4 hours at steady state2
  • In patients with T1DM, steady-state insulin levels are reached by at least 5 days of once-daily injections1
Clamp Study 1: The pharmacodynamics of Toujeo® at steady state after 8 days of daily injections was evaluated against Lantus® in a euglycemic clamp study of patients with T1DM (N=30) receiving injections of 0.4 U/kg once daily. The dose on day 8 was followed by a 36-hour euglycemic clamp.1,2

Clamp 1 Study Design


IN TWO PK/PD STUDIES, TOUJEO® DEMONSTRATED2,3

  • Consistent insulin release
  • Stable insulin effect that lasts all day and beyond
    • When taken once daily at the same time each day
  • Data supporting a flat PK profile

Read the Toujeo® PK/PD study publications at PubMed.gov by using the links below.


HOW TOUJEO® WORKS
This video highlights the important formulation differences between Toujeo® and Lantus®.

Toujeo® is a once-daily basal insulin with a reduced injection volume, a gradual insulin release, and a stable action profile.


TOUJEO®: REDUCED INJECTION VOLUME, SMALLER PRECIPITATE,
AND GRADUAL INSULIN RELEASE1,4

Toujeo®—a distinct formulation from Lantus®

Key differences in the formulation of Toujeo versus Lantus

Graphic demonstrates key differences in the formulation of Toujeo® versus that of Lantus®: a reduced injection volume for the same number of units and a smaller precipitate.

For illustrative purposes only.